The American Association for Cancer Research (AACR) requests NCI support for an innovative, unique, and intensive one-week educational experience (Integrative Molecular Epidemiology Workshop) to be repeated annually to accelerate the training of the next generation of cancer researchers who must be well-skilled in the integration of biology and epidemiology in studies of etiology and outcome. Of particular importance is the need to educate researchers in integrating modern and rapidly evolving omics technologies into state-of-the-art molecular epidemiology, as well the need to become facile in integrating diverse and high dimensional data. The Workshop is primarily targeted toward molecular epidemiologists, but the materials are designed to also be appropriate for geneticists, statisticians, bioinformaticians, molecular biologists, physician scientists and other who have completed basic coursework in epidemiology. The highly qualified faculty assembled to teach this workshop have expertise that spans these disciplines ensuring that all materials are of the highest quality and the most relevant content. The program will be reviewed annually by distinguished scientists who serve on the Board of Directors of the AACR, a scientific society of 35,638 members worldwide working in all aspects of basic, clinical, and translational cancer research. It is expected that the majority of the 50 attendees will be postdoctoral fellows and junior faculty, but a few advanced graduate students and mid-level/senior faculty will be eligible to participate. Based on our experiences with other courses, we expect the application process to be highly competitive, with at least twice the number of applications for the slots available. What will distinguish the focus of the workshop is the application of these technologies and approaches within an epidemiologic framework. Thus, all lectures and laboratories will be cognizant of issues like feasibility, scalability, quality control, and practical limitations. Forml didactic lectures will take place in the mornings with extensive time for discussion. Afternoons will be devoted to laboratories building upon the information provided in the morning lectures with problem- solving sessions and hands-on applications of statistical and bioinformatics methods. Participants will work collaboratively in small groups throughout the duration of the workshop. Cooperative group learning and problem solving activities will be used to ensure lively and active discussion with engaged learners. Finally, we will evaluate learning with measurable outcomes for the workshop overall and for individual lectures and laboratories. AACR has experienced staff and an excellent track record for administering other educational Workshops.

Public Health Relevance

The Integrative Molecular Epidemiology Workshop is designed to accelerate the training of the next generation of cancer researchers who must be well-skilled in the integration of biology and epidemiology in studies of etiology and outcome. There is a need for rapid and efficient translation of the emerging wealth of genomic, epigenomic and transcriptomic information to initiatives for cancer prevention and early detection, as well as to those for improving patient management. Inevitably this will mandate a growing emphasis on molecular epidemiology research and the application of research approaches intrinsic to epidemiology to other aspects of translational research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Education Projects (R25)
Project #
4R25CA174664-04
Application #
9128559
Study Section
Subcommittee F - Institutional Training and Education (NCI-F)
Program Officer
Korczak, Jeannette F
Project Start
2013-09-01
Project End
2018-08-31
Budget Start
2016-09-01
Budget End
2017-08-31
Support Year
4
Fiscal Year
2016
Total Cost
$207,685
Indirect Cost
$18,460
Name
American Association for Cancer Research
Department
Type
DUNS #
139203590
City
Philadelphia
State
PA
Country
United States
Zip Code
19106
Tafreshi, Narges K; Lloyd, Mark C; Proemsey, Joshua B et al. (2016) Evaluation of CAIX and CAXII Expression in Breast Cancer at Varied O2 Levels: CAIX is the Superior Surrogate Imaging Biomarker of Tumor Hypoxia. Mol Imaging Biol 18:219-31
Ovarian Cancer Association Consortium, Breast Cancer Association Consortium, and Consortium of Modifiers of BRCA1 and BRCA2 (see original citation for additional authors) (2016) No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecol Oncol 141:386-401
Sehovic, Ivana; Gwede, Clement K; Meade, Cathy D et al. (2016) A Web-Based Platform for Educating Researchers About Bioethics and Biobanking. J Cancer Educ 31:397-404
Schabath, M B; Welsh, E A; Fulp, W J et al. (2016) Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma. Oncogene 35:3209-16
Sudenga, Staci L; Ingles, Donna J; Pierce Campbell, Christine M et al. (2016) Genital Human Papillomavirus Infection Progression to External Genital Lesions: The HIM Study. Eur Urol 69:166-73
Muilenburg, Diego J; Beasley, Georgia M; Thompson, Zachary J et al. (2015) Burden of disease predicts response to isolated limb infusion with melphalan and actinomycin D in melanoma. Ann Surg Oncol 22:482-8
Stone, Jennifer; Thompson, Deborah J; Dos Santos Silva, Isabel et al. (2015) Novel Associations between Common Breast Cancer Susceptibility Variants and Risk-Predicting Mammographic Density Measures. Cancer Res 75:2457-67
Vansteenkiste, Johan F; Canon, Jean-Luc; De Braud, Filippo et al. (2015) Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study. J Thorac Oncol 10:1319-1327
Han, Dale; Han, Gang; Zhao, Xiuhua et al. (2015) Clinicopathologic predictors of survival in patients with desmoplastic melanoma. PLoS One 10:e0119716
Scortegagna, Marzia; Lau, Eric; Zhang, Tongwu et al. (2015) PDK1 and SGK3 Contribute to the Growth of BRAF-Mutant Melanomas and Are Potential Therapeutic Targets. Cancer Res 75:1399-412

Showing the most recent 10 out of 116 publications